About
Cancer Immunotherapy
CureTech is a biotechnology company developing broad-spectrum, immune-modulating products for the treatment and control of cancer. Its product line includes antibodies and peptide-based vaccines designed to modulate the immune response, allowing it to exert its anti-cancer activity in an effective manner. CureTech's lead humanized antibody product, pidilizumab (CT-011), is in Phase II clinical testing. Pidilizumab has shown promising results in attenuating tumor growth and eliminating tumor metastases in a variety of model systems. Several patents and pending patent applications worldwide protect the company's products. A licensing agreement for further development and commercialization of pidilizumab was signed with Medivation in 2014. In 2018, InSight Innovations acquired CureTech.
Identity
| Name | CureTech |
|---|---|
| Slug | curetech |
| Type / kind | startup |
| Crunchbase ID | curetech |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6stdMIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Feb 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Derech Menachem Begin 132, Tel Aviv-Yafo, Israel |
Web & social
| Website | http://curetechbio.com |
|---|---|
| https://www.linkedin.com/company/7018637 |
Classifications
Funding
| Total raised | $4.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}